Oncology and Melanoma
Research activity is centered on unresectable or metastatic melanoma, with particular attention to BRAF V600-mutated disease in inoperable stage III and metastatic stage IV settings.
- Advanced melanoma
- BRAF-mutated tumors
- Metastatic disease
The clinical focus includes patients with large, singular, stable to progressive metastases requiring local intervention alongside systemic treatment.
Local Tumor Control
Clinical interest extends to radiotherapy, surgery, and electrochemotherapy as local treatment options for melanoma metastases.
- Radiotherapy
- Surgical intervention
- Electrochemotherapy
These treatment areas are relevant for managing selected metastatic lesions in patients receiving targeted therapy.
Targeted Therapy in Melanoma
The sponsor’s research landscape includes melanoma care involving targeted treatment for BRAF V600 mutation-positive disease, with interest in combination approaches used in routine oncology practice.
- BRAF-targeted therapy
- MEK inhibition
- Combination systemic treatment
Clinical activity is aligned with management of patients already receiving Encorafenib and Binimetinib.
Outcome Assessment in Advanced Cancer Care
Research interest includes progression-free survival as a clinically relevant endpoint in the setting of local treatment for melanoma metastases.
- Disease progression
- Survival outcomes
- Treatment response
The focus is on evaluating how local control strategies relate to disease course in patients with advanced melanoma.
